ReviewClinical cancer research : an official journal of the American Association for Cancer Research2016
Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 84 citations in OpenAlex.
- Radiation Oncology-Biology Integration Network: Bridging the Gap between Biological Research and Clinical Practice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Synergistic Interactions Between Medicinal Plant Bioactive and Standard Chemotherapy in Gastric Cancer: Preclinical Evidence and Translational Pitfalls.Biomedicines · 2026Review
- C. Norman Coleman's Legacy in Radiation Research and Global Health: A Cancer Research and Care Perspective.Disaster medicine and public health preparedness · 2026Article
- Comparative analysis of molecular targeted radiosensitizers in 2D and 3D cancer cell line models.Acta oncologica (Stockholm, Sweden) · 2025Article
- Compensator-based small animal IMRT enables conformal preclinical dose painting: application to tumor hypoxia.Scientific reports · 2025Article
- The importance of standardization and challenges of dosimetry in conventional preclinical radiation biology research.The British journal of radiology · 2025Review
- Harnessing Senescence for Antitumor Immunity to Advance Cancer Treatment.Radiation research · 2024Article
- Recent advances in lung cancer organoid (tumoroid) research (Review).Experimental and therapeutic medicine · 2024Review
- The role of radiotherapy in the management of malignant peripheral nerve sheath tumors: a single-center retrospective cohort study.Journal of cancer research and clinical oncology · 2023Article
- Characterization of Inorganic Scintillator Detectors for Dosimetry in Image-Guided Small Animal Radiotherapy Platforms.Cancers · 2023Article
- A High Throughput Screen with a Clonogenic Endpoint to Identify Radiation Modulators of Cancer.Radiation research · 2023Article
- Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma.Molecular cancer therapeutics · 2023Article
- Combined proton radiography and irradiation for high-precision preclinical studies in small animals.Frontiers in oncology · 2022Article
- Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic.International journal of radiation oncology, biology, physics · 2021Article
- Screening and Validation of Molecular Targeted Radiosensitizers.International journal of radiation oncology, biology, physics · 2021Article
- Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations.International journal of radiation oncology, biology, physics · 2021Article
- 3D Breast Tumor Models for Radiobiology Applications.Cancers · 2021Review
- Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy.Journal of the National Cancer Institute · 2021Article
- Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.Molecular cancer therapeutics · 2021Article
- Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care.JNCI cancer spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
There is an urgent need to improve reproducibility and translatability of preclinical data to fully exploit opportunities for molecular therapeutics involving radiation and radiochemotherapy. For in vitro research, the clonogenic assay remains the current state-of-the-art of preclinical assays, whereas newer moderate and high-throughput assays offer the potential for rapid initial screening. Studies of radiation response modification by molecularly targeted agents can be improved using more physiologic 3D culture models. Elucidating effects on the cancer stem cells (CSC, and CSC-like) and developing biomarkers for defining targets and measuring responses are also important. In vivo studies are necessary to confirm in vitro findings, further define mechanism of action, and address immunomodulation and treatment-induced modification of the microenvironment. Newer in vivo models include genetically engineered and patient-derived xenograft mouse models and spontaneously occurring cancers in domesticated animals. Selection of appropriate endpoints is important for in vivo studies; for example, regrowth delay measures bulk tumor killing, whereas local tumor control assesses effects on CSCs. The reliability of individual assays requires standardization of procedures and cross-laboratory validation. Radiation modifiers must be tested as part of clinical standard of care, which includes radiochemotherapy for most tumors. Radiation models are compatible with but also differ from those used for drug screening. Furthermore, the mechanism of a drug as a chemotherapeutic agent may be different from its interaction with radiation and/or radiochemotherapy. This provides an opportunity to expand the use of molecular-targeted agents. Clin Cancer Res; 22(13); 3138-47. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.